Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure.
暂无分享,去创建一个
G. Fonarow | L. Stevenson | J. Tillisch | J. Moriguchi | C. Chelimsky-Fallick | M. Hamilton | A. Steimle | A. Kartashov
[1] D R Nul,et al. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicéntricos en Argentina. , 1997, Journal of the American College of Cardiology.
[2] T. Nozawa,et al. Energetically optimal left ventricular pressure for the failing human heart. , 1996, Circulation.
[3] R. Carney,et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. , 1995, The New England journal of medicine.
[4] P C Deedwania,et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.
[5] G. Fonarow,et al. Improvement in exercise capacity of candidates awaiting heart transplantation. , 1995, Journal of the American College of Cardiology.
[6] H. Doval,et al. Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.
[7] M. Fisher,et al. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors. , 1993, Journal of the American College of Cardiology.
[8] M. Anguita,et al. Clinical and hemodynamic predictors of survival in patients aged < 65 years with severe congestive heart failure secondary to ischemic or nonischemic dilated cardiomyopathy. , 1993, The American journal of cardiology.
[9] D. Renlund,et al. Lisinopril Lowers Cardiac Adrenergic Drive and Increases, 8‐Recept or Density in the Failing Human Heart , 1993, Circulation.
[10] F. Tristani,et al. Hydralazine and Isosorbide Dinitrate Combination Improves Exercise Tolerance in Heart Failure Results from V‐HeFT I and V‐HeFT II , 1993, Circulation.
[11] R. Bolman,et al. Trends in patient selection for heart transplantation. , 1993, Journal of the American College of Cardiology.
[12] U. Elkayam,et al. Persistent hemodynamic improvement with short-term nitrate therapy in patients with chronic congestive heart failure already treated with captopril. , 1992, The American journal of cardiology.
[13] S. Yusuf,et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. , 1992, Circulation.
[14] S. Yusuf,et al. Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term: Progression of Left Ventricular Dysfunction in Patients With Heart Failure , 1992, Circulation.
[15] F. Cobb,et al. Central hemodynamic response to exercise in patients with chronic heart failure. , 1992, Chest.
[16] P. Poole‐Wilson,et al. Blood flow and skeletal muscle in patients with heart failure. , 1992, Chest.
[17] M. Kukin. Vasodilator therapy and survival in chronic congestive heart failure. , 1992, Journal of the American College of Cardiology.
[18] M. Luu,et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. , 1992, Journal of the American College of Cardiology.
[19] J. Juggi,et al. Vasodilator therapy: interaction of nitrates with angiotensin-converting enzyme inhibitors. , 1991, The Canadian journal of cardiology.
[20] F. Tristani,et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.
[21] K. Weber,et al. Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.
[22] J R Wilson,et al. Value of Peak Exercise Oxygen Consumption for Optimal Timing of Cardiac Transplantation in Ambulatory Patients With Heart Failure , 1991, Circulation.
[23] M. Woo,et al. Sustained reduction in valvular regurgitation and atrial volumes with tailored vasodilator therapy in advanced congestive heart failure secondary to dilated (ischemic or idiopathic) cardiomyopathy. , 1991, The American journal of cardiology.
[24] W. Grossman,et al. Effects of coronary venous pressure on left ventricular diastolic distensibility. , 1990, Circulation research.
[25] A. Katz. Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. , 1990, The New England journal of medicine.
[26] M. Schwaiger,et al. Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced heart failure. , 1990, Journal of the American College of Cardiology.
[27] L. Stevenson,et al. Exercise capacity for survivors of cardiac transplantation or sustained medical therapy for stable heart failure. , 1990, Circulation.
[28] A. Maisel,et al. Regulation of cardiac beta-adrenergic receptors by captopril. Implications for congestive heart failure. , 1989, Circulation.
[29] R. Cody,et al. Age-related hemodynamic, renal, and hormonal differences among patients with congestive heart failure. , 1989, Archives of internal medicine.
[30] H. Drexler,et al. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial. , 1989, Circulation.
[31] R. Dietz,et al. Influence of captopril on the arterial baroreceptor reflex in patients with heart failure. , 1988, European heart journal.
[32] M. Schwaiger,et al. Effects of afterload reduction (diuretics and vasodilators) on left ventricular volume and mitral regurgitation in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1987, The American journal of cardiology.
[33] L. Stevenson,et al. Maintenance of cardiac output with normal filling pressures in patients with dilated heart failure. , 1986, Circulation.
[34] S. R. Cohen,et al. Contribution of reduced mitral regurgitant volume to vasodilator effect in severe left ventricular failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. , 1986, The American journal of cardiology.
[35] C. Leddy,et al. Hemodynamic effects of vasodilators and long-term response in heart failure. , 1984, Journal of the American College of Cardiology.
[36] W. Laskey,et al. Matching of myocardial oxygen consumption to mechanical load in human left ventricular hypertrophy and dysfunction. , 1984, Journal of the American College of Cardiology.
[37] B. Massie,et al. Controlled Trial of Captopril in Chronic Heart Failure: A Rest and Exercise Hemodynamic Study , 1983, Circulation.
[38] R. Magorien,et al. Improved Exercise Capacity and Differing Arterial and Venous Tolerance During Chronic Isosorbide Dinitrate Therapy for Congestive Heart Failure , 1983, Circulation.
[39] G. Francis,et al. Medical management of terminal cardiomyopathy , 1982 .
[40] B. Massie,et al. Long‐term Vasodilator Therapy for Heart Failure: Clinical Response and its Relationship to Hemodynamic Measurements , 1981, Circulation.
[41] J. Cohn,et al. Treatment of refractory heart failure with infusion of nitroprusside. , 1974, The New England journal of medicine.
[42] W. Parmley,et al. Beneficial Effects of Vasodilator Agents in Severe Mitral Regurgitation Due to Dysfunction of Subvalvar Apparatus , 1973, Circulation.
[43] R. Russell,et al. Effects of increasing left ventricular filling pressure in patients with acute myocardial infarction , 1970 .